Alzamend Neuro Files 8-K with Corporate Updates

TL;DR

ALZN filed an 8-K on 7/12/24 for corporate updates and financial docs.

AI Summary

Alzamend Neuro, Inc. filed an 8-K on July 12, 2024, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and financial statements/exhibits. The company is incorporated in Delaware and its principal executive offices are located in Atlanta, GA.

Why It Matters

This filing indicates routine corporate actions and disclosures, providing transparency to investors regarding the company's governance and financial reporting.

Risk Assessment

Risk Level: low — The filing primarily concerns routine corporate disclosures and amendments, not significant operational or financial events.

Key Players & Entities

• Alzamend Neuro, Inc. (company) — Registrant
• July 12, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Atlanta, GA (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value ALZN The Nasdaq Capital M

Filing Documents

• b7112428k.htm (8-K) — 29KB
• ex3_1.htm (EX-3.1) — 2KB
• ex99_1.htm (EX-99.1) — 7KB
• ex31-001.jpg (GRAPHIC) — 40KB
• ex31-002.jpg (GRAPHIC) — 171KB
• alzamendlogo_regmark.jpg (GRAPHIC) — 17KB
• 0001214659-24-012340.txt ( ) — 532KB
• alzn-20240712.xsd (EX-101.SCH) — 3KB
• alzn-20240712_lab.xml (EX-101.LAB) — 33KB
• alzn-20240712_pre.xml (EX-101.PRE) — 22KB
• b7112428k_htm.xml (XML) — 4KB

03 AMENDMENTS TO ARTICLES OF INCORPORATION; CHANGE IN FISCAL YEAR

ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION; CHANGE IN FISCAL YEAR On July 10, 2024, Alzamend Neuro, Inc. (the " Company "), filed an amendment to the Company's Certificate of Incorporation (the " Amendment ") with the State of Delaware to effectuate a reverse stock split of the issued and outstanding shares of the Company's common stock, $0.0001 par value (" Common Stock ") by a ratio of one-for-ten (the " Reverse Stock Split "). The Reverse Stock Split will become effective in the The stockholders of the Company, at an annual meeting of such stockholders on April 30, 2024 , authorized the Company's board of directors (the " Board ") to effectuate a reverse stock split within a range of one-for-two to one-for-twenty. On June 24, 2024, the Board approved the Amendment to effectuate the Reverse Stock Split. Beginning with the opening of trading on July 16, 2024, the Common Stock will trade on The Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 02262M506. As a result of the Reverse Stock Split, each ten (10) shares of Common Stock issued and outstanding prior to the Reverse Stock Split will be converted into one (1) share of Common Stock, with no change in authorized shares or par value per share, and the number of shares of Common Stock outstanding will be reduced from approximately 7,981,763 shares to approximately 798,176 shares . A ll options, warrants, and any other similar instruments, convertible into, or exchangeable or exercisable for, shares of Common Stock will be proportionally adjusted. The foregoing description does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, which is attached hereto as Exhibit 3.1 , and incorporated herein by reference.

01 REGULATION FD DISCLOSURE

ITEM 7.01 REGULATION FD DISCLOSURE On July 12, 2024, the Company issued a press release announcing the Reverse Stock Split, a copy of which press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. In accordance with General Instruction B.2 of Form 8-K, the information under this item, Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. This report will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD. The Securities and Exchange Commission encourages registrants to disclose forward-looking information so that investors can better understand the future prospects of a registrant and make informed investment decisions. This Current Report on Form 8-K and exhibits may contain these types of statements, which are "forward-looking reflect the Registrant's judgment as of the date of this Current Report on Form 8-K. Forward-looking statements may relate to, among other things, operating results and are indicated by words or phrases such as "expects," "should," "will," and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this Current Report on Form 8-K. Investors are cautioned not to rely unduly on forward-looking

01 FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS (d) Exhibits: Exhibit No. Description 3.1 Certificate of Amendment to Certificate of Incorporation filed with the Delaware Secretary of State on July 10, 2024. 99.1 Press Release dated July 12, 2024. 101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALZAMEND NEURO, INC. Dated: July 12, 2024 /s/ Henry Nisser Henry Nisser Executive Vice President and General Counsel 3

View Full Filing

View this 8-K filing on SEC EDGAR